QTc Interval-Prolonging Medications Among Patients With Lung Cancer: Implications for Clinical Trial Eligibility and Clinical Care

Tri Le, Hui Yang, Sawsan Rashdan, Mark S. Link, Vlad G. Zaha, Carlos Alvarez, David E. Gerber

Research output: Contribution to journalArticle

Abstract

The use of corrected QT (QTc) interval-prolonging medications is a common exclusion criterion in clinical trials. To explore its potential effect, a cohort of patients with lung cancer in the Veterans Affairs system was studied to determine the prevalence of such drugs. Among 280,068 patients, 28.4% had been prescribed ≥1 QTc-interval prolonging medication, and 7.3% had been prescribed ≥2, warranting further research into the actual clinical risks and optimal management of QTc-prolonging medications in populations with cancer.

Original languageEnglish (US)
Pages (from-to)21-27.e5
JournalClinical lung cancer
Volume21
Issue number1
DOIs
StatePublished - Jan 2020

Keywords

  • Clinical research
  • Exclusion criteria
  • Oncocardiology
  • Targeted therapy
  • Thoracic oncology

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'QTc Interval-Prolonging Medications Among Patients With Lung Cancer: Implications for Clinical Trial Eligibility and Clinical Care'. Together they form a unique fingerprint.

  • Cite this